Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Frisco, Texas – November 13, 2009– Recursion Software, a long time leader in cross-platform C++ programming tools, has released a new version of its C++ Toolkit for the Texas Instruments Da Vinci™ and ...

EPS estimates have risen 2.6% over the past 60 days, though revenue expectations have remained essentially flat over the same period. Eight analysts rate the stock a Buy, with a mean price target of ...

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous ...